Invesco Ltd. Ocugen, Inc. Transaction History

Invesco Ltd.

$516 Billion
Q4 2024

A detailed history of Invesco Ltd. transactions in Ocugen, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 173,553 shares of OCGN stock, worth $95,454. This represents 0.0% of its overall portfolio holdings.

Number of Shares

173,553

Previous 124,874 38.98%

Holding current value

$95,454

Previous $123,000 12.2%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$0.72 - $1.08 $35,048 - $52,573	48,679 Added 38.98%	173,553 $138,000
Q3 2024 Nov 12, 2024	BUY	$0.98 - $1.95 $1,371 - $2,728	1,399 Added 1.13%	124,874 $123,000
Q2 2024 Aug 13, 2024	BUY	$1.18 - $1.98 $145,700 - $244,480	123,475 New	123,475 $191,000
Q3 2023 Nov 13, 2023	BUY	$0.4 - $0.62 $1,419 - $2,199	3,548 Added 4.84%	76,797 $30,000
Q2 2023 Aug 11, 2023	SELL	$0.45 - $0.88 $1,515 - $2,962	-3,367 Reduced 4.39%	73,249 $39,000
Q1 2023 May 12, 2023	SELL	$0.82 - $1.33 $5,596 - $9,077	-6,825 Reduced 8.18%	76,616 $65,000
Q4 2022 Feb 13, 2023	SELL	$1.11 - $1.87 $9,669 - $16,289	-8,711 Reduced 9.45%	83,441 $108,000
Q3 2022 Nov 14, 2022	BUY	$1.75 - $3.1 $18,607 - $32,962	10,633 Added 13.04%	92,152 $164,000
Q2 2022 Aug 15, 2022	BUY	$1.83 - $3.45 $5,136 - $9,684	2,807 Added 3.57%	81,519 $185,000
Q1 2022 May 16, 2022	SELL	$2.34 - $4.72 $4,885 - $9,855	-2,088 Reduced 2.58%	78,712 $260,000
Q4 2021 Feb 14, 2022	SELL	$4.38 - $15.67 $109,062 - $390,183	-24,900 Reduced 23.56%	80,800 $368,000
Q3 2021 Nov 15, 2021	BUY	$6.36 - $8.51 $137,115 - $183,467	21,559 Added 25.62%	105,700 $759,000
Q2 2021 Aug 17, 2021	BUY	$5.52 - $15.68 $464,458 - $1.32 Million	84,141 New	84,141 $675,000

Others Institutions Holding OCGN

# of Institutions

123

Shares Held

68.6M

Call Options Held

478K

Put Options Held

253K

View Full List

About Ocugen, Inc.

Ticker OCGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,566,000
Market Cap $119M
Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...

More about OCGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account